← Back to Search

Implant

iFuse TORQ for Sacroiliac Joint Dysfunction

Phase 4
Recruiting
Research Sponsored by SI-BONE, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 21 at time of screening
Baseline SIJ pain score of at least 5 on 0-10 numerical rating scale
Must not have
ASA score 4 or 5
Current diagnosis of fibromyalgia
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at baseline, 1-, 3-, 6-, 12-, and 24-months
Awards & highlights

Summary

This trial is testing a new device called iFuse TORQ that helps join bones in the lower back. It aims to help patients with lower back pain or instability by stabilizing and fusing their sacroiliac joint. The iFuse Implant System® has been used in minimally invasive sacroiliac joint fusion to relieve pain and improve quality of life in patients with sacroiliac joint degeneration or disruption.

Who is the study for?
This trial is for adults over 21 with sacroiliac joint dysfunction, experiencing lower back or buttock pain for at least 6 months that hasn't improved with non-surgical care. Participants must have a BMI under 35 and significant disability and pain as measured by specific scales. Exclusions include severe other back issues, certain systemic diseases, allergies to titanium, current infections, substance abuse, pregnancy plans within two years, involvement in litigation related to disability or workers' compensation claims.
What is being tested?
The STACI study is testing the iFuse TORQ implant system's effectiveness in treating sacroiliac joint dysfunction. This prospective multicenter study will evaluate how well this new device can alleviate pain and improve function compared to existing treatments.
What are the potential side effects?
While not explicitly listed here, potential side effects may include typical surgical risks such as infection risk increase due to surgery, allergic reactions to materials (titanium), nerve damage around the implant site leading to numbness or weakness, and possible increased pain during recovery.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am over 21 years old.
Select...
My baseline pain in the sacroiliac joint is at least a 5 out of 10.
Select...
I have been diagnosed with sacroiliac joint dysfunction.
Select...
I have had lower back or buttock pain for over 6 months that hasn't improved with non-surgical treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My health is severely limited by my illness.
Select...
I have been diagnosed with fibromyalgia.
Select...
I have severe osteoporosis or a history of fractures due to it.
Select...
I do not have a psychiatric condition that could affect my participation.
Select...
My body can safely accommodate the medical device.
Select...
I have an infection that could make surgery risky.
Select...
I have severe back pain not caused by cancer.
Select...
I do not have conditions like ankylosing spondylitis affecting my sacroiliac joint.
Select...
I have had a major injury to my pelvis in the last year.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at baseline, 1-, 3-, 6-, 12-, and 24-months
This trial's timeline: 3 weeks for screening, Varies for treatment, and at baseline, 1-, 3-, 6-, 12-, and 24-months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in SI joint pain measured by numerical rating scale (NRS)
Secondary study objectives
Evidence of bone binding
Improvement from baseline in SI joint (SIJ) pain
Improvement from baseline in disability
+2 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Use of iFuse TORQ for SI Joint FusionExperimental Treatment1 Intervention
Participants with SI joint dysfunction are treated with iFuse TORQ.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Sacroiliac Joint Dysfunction (SIJD) aim to stabilize the joint and reduce pain. The iFuse TORQ implant system, for example, promotes bone growth and fusion, which helps to stabilize the sacroiliac joint by creating a solid bony bridge across the joint. This stabilization is crucial for reducing the abnormal motion that causes pain. Other interventional therapies, such as steroid injections and radiofrequency ablation, target pain relief by reducing inflammation or disrupting nerve signals. These treatments are important for SIJD patients as they address both the mechanical instability and the pain, improving overall function and quality of life.

Find a Location

Who is running the clinical trial?

SI-BONE, Inc.Lead Sponsor
12 Previous Clinical Trials
1,780 Total Patients Enrolled
Robyn Capobianco, PhDStudy DirectorSI-BONE
5 Previous Clinical Trials
2,742 Total Patients Enrolled

Media Library

iFuse TORQ (Implant) Clinical Trial Eligibility Overview. Trial Name: NCT05870488 — Phase 4
Sacroiliac Joint Dysfunction Research Study Groups: Use of iFuse TORQ for SI Joint Fusion
Sacroiliac Joint Dysfunction Clinical Trial 2023: iFuse TORQ Highlights & Side Effects. Trial Name: NCT05870488 — Phase 4
iFuse TORQ (Implant) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05870488 — Phase 4
~60 spots leftby May 2026